Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $395,000.

  • Keros Therapeutics' Depreciation & Amortization (CF) rose 25.80% to $395,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 25.96%. This contributed to the annual value of $1.2 million for FY2024, which is 50.80% up from last year.
  • As of Q3 2025, Keros Therapeutics' Depreciation & Amortization (CF) stood at $395,000, which was up 6.76% from $370,000 recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Depreciation & Amortization (CF) ranged from a high of $395,000 in Q3 2025 and a low of $80,000 during Q1 2021.
  • Over the past 3 years, Keros Therapeutics' median Depreciation & Amortization (CF) value was $306,000 (recorded in 2024), while the average stood at $286,636.
  • Per our database at Business Quant, Keros Therapeutics' Depreciation & Amortization (CF) spiked by 238.46% in 2022 and then crashed by 37.99% in 2023.
  • Keros Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $104,000 in 2021, then rose by 22.12% to $127,000 in 2022, then skyrocketed by 94.49% to $247,000 in 2023, then surged by 34.41% to $332,000 in 2024, then climbed by 25.80% to $395,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $395,000 for Q3 2025, versus $370,000 for Q2 2025 and $344,000 for Q1 2025.